Effect of Mirtazapine Treatment on Serum Levels of Brain-Derived Neurotrophic Factor and Tumor Necrosis Factor-α in Patients of Major Depressive Disorder with Severe Depression

Pharmacology

Volumn 97, Issue 3-4, 2016, Pages 184-188

  Gupta, Rachna ^a   Gupta, Keshav ^a   Tripathi, A K ^a   Bhatia, M S ^a   Gupta, Lalit K ^b  

^a UNIVERSITY COLLEGE OF MEDICAL SCIENCES   (India)

^b LADY HARDINGE MEDICAL COLLEGE   (India)

Author keywords

Brain derived neurotrophic factor; Depression; Major depressive disorder; Mirtazapine; Tumor necrosis factor

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; MIRTAZAPINE; TUMOR NECROSIS FACTOR ALPHA; BRAIN-DERIVED NEUROTROPHIC FACTOR, HUMAN; MIANSERIN; TRICYCLIC ANTIDEPRESSANT AGENT; TUMOR NECROSIS FACTOR;

ADULT; AGITATION; ANOREXIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DSM-IV; FEMALE; HAMILTON DEPRESSION RATING SCALE; HEADACHE; HUMAN; INSOMNIA; MAJOR DEPRESSION; MALE; NAUSEA; OBSERVATIONAL STUDY; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; TREATMENT DURATION; TREMOR; WEIGHT GAIN; XEROSTOMIA; ADOLESCENT; ANALOGS AND DERIVATIVES; BLOOD; DEPRESSION; DEPRESSIVE DISORDER, MAJOR; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIDEPRESSIVE AGENTS, TRICYCLIC; BRAIN-DERIVED NEUROTROPHIC FACTOR; DEPRESSION; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; MIANSERIN; MIDDLE AGED; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84957922326     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000444220     Document Type: Article

References (29)

1. Timonen M, Liukkonen T: Management of depression in adults. BMJ 2008; 336: 435-439.
2. Brunoni AR, Lopes M, Fregni F: A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression. Int J Neuropsychopharmacol 2008; 11: 1169-1180.
3. Duman RS, Heninger GR, Nestler EJ: A molecular and cellular theory of depression. Arch Gen Psychiatry 1997; 54: 597-606.
4. Hoshaw BA, Malberg JE, Lucki I: Central administration of IGF-I and BDNF leads to long-lasting antidepressant-like effects. Brain Res 2005; 1037: 204-208.
5. Zhang Y, Gu F, Chen J, Dong W: Chronic antidepressant administration alleviates frontal and hippocampal BDNF deficits in CUMS rat. Brain Res 2010; 1366: 141-148.
6. Rogoz Z, Skuza G, Legutko B: Repeated treatment with mirtazepine induces brain-derived neurotrophic factor gene expression in rats. J Physiol Pharmacol 2005; 56: 661-671.
7. Hashimoto K, Shimizu E, Iyo M: Critical role of brain-derived neurotrophic factor in mood disorders. Brain Res Brain Res Rev 2004; 45: 104-114.
8. Sen S, Duman R, Sanacora G: Serum brainderived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiatry 2008; 64: 527-532.
9. Cooke JD, Grover LM, Spangler PR: Venlafaxine treatment stimulates expression of brain-derived neurotrophic factor protein in frontal cortex and inhibits long-term potentiation in hippocampus. Neuroscience 2009; 162: 1411-1419.
10. Dias BG, Banerjee SB, Duman RS, Vaidya VA: Differential regulation of brain derived neurotrophic factor transcripts by antidepressant treatments in the adult rat brain. Neuropharmacology 2003; 45: 553-563.
11. Altar CA, Whitehead RE, Chen R, Wortwein G, Madsen TM: Effects of electroconvulsive seizures and antidepressant drugs on brain-derived neurotrophic factor protein in rat brain. Biol Psychiatry 2003; 54: 703-709.
12. Schulte-Herbruggen O, Fuchs E, Abumaria N, Ziegler A, Danker-Hopfe H, Hiemke C, et al: Effects of escitalopram on the regulation of brain-derived neurotrophic factor and nerve growth factor protein levels in a rat model of chronic stress. J Neurosci Res 2009; 87: 2551-2560.
13. Gervasoni N, Aubry JM, Bondolfi G, Osiek C, Schwald M, Bertschy G, et al: Partial normalization of serum brain-derived neurotrophic factor in remitted patients after a major depressive episode. Neuropsychobiology 2005; 51: 234-238.
14. Gonul AS, Akdeniz F, Taneli F, Donat O, Eker C, Vahip S: Effect of treatment on serum brain-derived neurotrophic factor levels in depressed patients. Eur Arch Psychiatry Clin Neurosci 2005; 255: 381-386.
15. Basterzi AD, Yazici K, Aslan E, Delialioglu N, Tasdelen B, Tot Acar S, et al: Effects of fluoxetine and venlafaxine on serum brain derived neurotrophic factor levels in depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33: 281-285.
16. Wolkowitz OM, Wolf J, Shelly W, Rosser R, Burke HM, Lerner GK, et al: Serum BDNF levels before treatment predict SSRI response in depression. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35: 1623-1630.
17. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, et al: A meta-analysis of cytokines in major depression. Biol Psychiatry 2010; 67: 446-457.
18. Hannestad J, DellaGioia N, Bloch M: The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology 2011; 36: 2452-2459.
19. Tuglu C, Kara SH, Caliyurt O, Vardar E, Abay E: Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder. Psychopharmacology (Berl) 2003; 170: 429-433.
20. Janssen DG, Caniato RN, Verster JC, Baune BT: A psychoneuroimmunological review on cytokines involved in antidepressant treatment response. Hum Psychopharmacol 2010; 25: 201-215.
21. Anttila SA, Leinonen EV: A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev 2001; 7: 249-264.
22. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR. Washington, American Psychiatric Association, 2000.
23. Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62.
24. Versiani M, Moreno R, Ramakers-van Moorsel CJ, Schutte AJ: Comparison of the effects of mirtazapine and fluoxetine in severely depressed patients. CNS Drugs 2005; 19: 137-146.
25. Kang RH, Chang HS, Wong ML, Choi MJ, Park JY, Lee HY, et al: Brain-derived neurotrophic factor gene polymorphisms and mirtazapine responses in Koreans with major depression. J Psychopharmacol 2010; 24: 1755-1763.
26. Katsuki A, Yoshimura R, Kishi T, Hori H, Umene-Nakano W, Ikenouchi-Sugita A, et al: Serum levels of brain-derived neurotrophic factor (BDNF), BDNF gene Val66Met polymorphism, or plasma catecholamine metabolites, and response to mirtazapine in Japanese patients with major depressive disorder (MDD). CNS Spectr 2012; 17: 155-163.
27. Deuschle M, Gilles M, Scharnholz B, Lederbogen F, Lang UE, Hellweg R: Changes of serum concentrations of brain-derived neurotrophic factor (BDNF) during treatment with venlafaxine and mirtazapine: role of medication and response to treatment. Pharmacopsychiatry 2013; 46: 54-58.
28. Engel D, Zomkowski AD, Lieberknecht V, Rodrigues AL, Gabilan NH: Chronic administration of duloxetine and mirtazapine downregulates proapoptotic proteins and upregulates neurotrophin gene expression in the hippocampus and cerebral cortex of mice. J Psychiatr Res 2013; 47: 802-808.
29. Manikowska K, Mikolajczyk M, Mikolajczak PL, Bobkiewicz-Kozlowska T: The influence of mianserin on TNF-alpha, IL-6 and IL-10 serum levels in rats under chronic mild stress. Pharmacol Rep 2014; 66: 22-27.